Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Waterways Polluted With Antibiotics, Antimicrobials And Antifungals
Antibiotics, antimicrobials and antifungals are seeping into the waterways of North America, Europe and East Asia, according to an investigation published in the peer-reviewed journal Environmental Health Perspectives (EHP). Authored by Université de Montréal and Environment Canada researchers, the review found that consumption of anti-infectives for human and agriculture use contributes to their release into the environment and even into drinking water.
generic viagra online
Safe New Treatment Combination For Head And Neck Cancer Patients
Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI). The results were disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla.
News of the day
Prometheus Announces New Findings Regarding Patients At Risk For Celiac Disease At DDW
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding a correlation between an important serologic marker used in the detection of Crohn"s disease and particular genetic markers in patients at risk for celiac disease. In an oral presentation yesterday at Digestive Disease Week (DDW) in Chicago, Prometheus reported a statistically significant correlation between antibodies to the flagellin CBir1 and HLA haplotypes DQ2.5 and DQ8 in a study of 5,406 patients at risk for celiac disease who are EMA positive. Blood and serum samples were analyzed using PROMETHEUS(R) Celiac PLUS and PROMETHEUS(R) IBD Serology 7 diagnostic tests.
Medical Devices

Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict From Abbott Laboratories

Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit. "We are pleased that the jury has ruled in our favor in the patent litigation case against Abbott," said Kim Taylor, President, Centocor Ortho Biotech Inc. The patent in question relates to the company"s anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor, for which Centocor is the exclusive licensee. "We are particularly gratified that the jury recognized our valuable intellectual property, finding our patent both valid and infringed. We will continue to assert intellectual property rights for our immunology therapies, as they offer significant advances in treatment for patients with a number of immune mediated inflammatory diseases," Taylor added. Centocor Ortho Biotech Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009